Intention-to-treat analysis keeps all trial data, showing true drug effects, even with dropouts. It contrasts with per-protocol analysis, where dropout data is excluded, possibly skewing results.

Last week, Jake Colvin, president of the National Foreign Trade Council (NFTC), posted a really thoughtful piece that can be found here on the NFTC website. It is a reflection on a disturbing trend in ...